PubMed

Treatment interruption of highly active antiretroviral therapy in patients with nadir CD4 cell counts >200 cells/mm3.

Toulson AR, Harrigan R, Heath K, Yip B, Brumme ZL, Harris M, Hogg RS, Montaner JS.

J Infect Dis. 2005 Nov 15;192(10):1787-93. Epub 2005 Oct 5.PMID: 16235178 [PubMed - indexed for MEDLINE]Related articles

Antiretroviral resistance among HIV-infected persons who have died in British Columbia, in the era of modern antiretroviral therapy.

Recsky MA, Brumme ZL, Chan KJ, Wynhoven B, Yip B, Dong WW, Heath KV, Montaner JS, Levy AR, Hogg RS, Harrigan PR.

J Infect Dis. 2004 Jul 15;190(2):285-92. Epub 2004 Jun 11.PMID: 15216463 [PubMed - indexed for MEDLINE]Related articles

Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.

Wood E, Hogg RS, Heath KV, de la Rosa R, Lee N, Yip B, O'Shaughnessy MV, Montaner JS.

AIDS. 2003 Dec 5;17(18):2629-34.PMID: 14685057 [PubMed - indexed for MEDLINE]Related articles

Highly active antiretroviral therapy: physician experience and enhanced adherence to prescription refill.

Delgado J, Heath KV, Yip B, Marion S, Alfonso V, Montaner JS, O'Shaughnessy MV, Hogg RS.

Antivir Ther. 2003 Oct;8(5):471-8.PMID: 14640395 [PubMed - indexed for MEDLINE]Related articles

Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.

Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS.

Antivir Ther. 2003 Oct;8(5):379-84.PMID: 14640384 [PubMed - indexed for MEDLINE]Related articles

Interventional cardiovascular procedures among HIV-infected individuals on antiretroviral therapy 1995-2000.

Braitstein P, Yip B, Heath KV, Levy AR, Montaner JS, Humphries K, Kiely FM, O'Shaughnessy MV, Hogg RS.

AIDS. 2003 Sep 26;17(14):2071-5.PMID: 14502010 [PubMed - indexed for MEDLINE]Related articles

Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver.

Craib KJ, Spittal PM, Wood E, Laliberte N, Hogg RS, Li K, Heath K, Tyndall MW, O'Shaughnessy MV, Schechter MT.

CMAJ. 2003 Jan 7;168(1):19-24.PMID: 12515780 [PubMed - indexed for MEDLINE]Related articlesFree article

Incidence of morphological and lipid abnormalities: gender and treatment differentials after initiation of first antiretroviral therapy.

Heath KV, Chan KJ, Singer J, O'Shaughnessy MV, Montaner JS, Hogg RS.

Int J Epidemiol. 2002 Oct;31(5):1016-20.PMID: 12435777 [PubMed - indexed for MEDLINE]Related articlesFree article

Intentional nonadherence due to adverse symptoms associated with antiretroviral therapy.

Heath KV, Singer J, O'Shaughnessy MV, Montaner JS, Hogg RS.

J Acquir Immune Defic Syndr. 2002 Oct 1;31(2):211-7.PMID: 12394800 [PubMed - indexed for MEDLINE]Related articles

Antiretroviral treatment patterns and incident HIV-associated morphologic and lipid abnormalities in a population-based chort.

Heath KV, Hogg RS, Singer J, Chan KJ, O'Shaughnessy MV, Montaner JS.

J Acquir Immune Defic Syndr. 2002 Aug 1;30(4):440-7.PMID: 12138351 [PubMed - indexed for MEDLINE]Related articles

Intermittent use of triple-combination therapy is predictive of mortality at baseline and after 1 year of follow-up.

Hogg RS, Heath K, Bangsberg D, Yip B, Press N, O'Shaughnessy MV, Montaner JS.

AIDS. 2002 May 3;16(7):1051-8.PMID: 11953472 [PubMed - indexed for MEDLINE]Related articles

Correlates of suicide attempts in an open cohort of young men who have sex with men.

Botnick MR, Heath KV, Cornelisse PG, Strathdee SA, Martindale SL, Hogg RS.

Can J Public Health. 2002 Jan-Feb;93(1):59-62.PMID: 11925703 [PubMed - indexed for MEDLINE]Related articles